MD3280727T2 - Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora - Google Patents

Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora

Info

Publication number
MD3280727T2
MD3280727T2 MDE20180158T MDE20180158T MD3280727T2 MD 3280727 T2 MD3280727 T2 MD 3280727T2 MD E20180158 T MDE20180158 T MD E20180158T MD E20180158 T MDE20180158 T MD E20180158T MD 3280727 T2 MD3280727 T2 MD 3280727T2
Authority
MD
Moldova
Prior art keywords
type
tgf
extracellular domain
beta
arm
Prior art date
Application number
MDE20180158T
Other languages
English (en)
Inventor
Ravindra Kumar
Asya Grinberg
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MD3280727T2 publication Critical patent/MD3280727T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

În anumite aspecte, dezvăluirea redă complecşi polipeptidici heteromerici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor de serină/treonină kinază tip I al familiei TGF-beta sau un domeniu extracelular al unui receptor de serină/treonină kinază tip II al familiei TGF-beta. În unele modalităţi de realizare, dezvăluirea redă complecşi polipeptidici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor tip II selectat dintre: ActRIIA, ActRIIB, TGFBRII, BMPRII, şi MISRII. În unele modalităţi de realizare, dezvăluirea redă complecşi polipeptidici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor tip I selectat dintre : ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, şi ALK7. Opţional complexul solubil este un heterodimer. În anumite aspecte, astfel de complecşi polipeptidici solubili se pot utiliza pentru tratamentul sau prevenirea a diferite afecţiuni asociate cu TGF-beta, incluzând fără limitare boli sau tulburări asociate cu, de exemplu, cancer, muşchi, os, grăsime, celule roşii din sânge, metabolism, fibroză şi alte ţesuturi care sunt afectate de unul sau mai mulţi liganzi ai superfamiliei TGF-beta.
MDE20180158T 2015-04-06 2016-04-06 Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora MD3280727T2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143579P 2015-04-06 2015-04-06
US201562259422P 2015-11-24 2015-11-24
PCT/US2016/026275 WO2016164501A1 (en) 2015-04-06 2016-04-06 Single-arm type i and type ii receptor fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MD3280727T2 true MD3280727T2 (ro) 2021-06-30

Family

ID=57015654

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180158T MD3280727T2 (ro) 2015-04-06 2016-04-06 Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora

Country Status (21)

Country Link
US (3) US10358476B2 (ro)
EP (2) EP3865505A1 (ro)
JP (2) JP6810702B2 (ro)
KR (1) KR20170141215A (ro)
CN (3) CN113683708A (ro)
AU (2) AU2016246602B2 (ro)
CA (1) CA2981793A1 (ro)
CY (1) CY1124247T1 (ro)
DK (1) DK3280727T3 (ro)
ES (1) ES2864850T3 (ro)
HK (1) HK1252958A1 (ro)
HR (1) HRP20210411T1 (ro)
HU (1) HUE054180T2 (ro)
LT (1) LT3280727T (ro)
MA (1) MA53883A (ro)
MD (1) MD3280727T2 (ro)
PL (1) PL3280727T3 (ro)
PT (1) PT3280727T (ro)
RS (1) RS61728B1 (ro)
SI (1) SI3280727T1 (ro)
WO (1) WO2016164501A1 (ro)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
KR20170141215A (ko) 2015-04-06 2017-12-22 악셀레론 파마 인코포레이티드 싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MA54328A (fr) 2015-04-06 2021-10-06 Acceleron Pharma Inc Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
WO2017176938A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
WO2018067874A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
US11440949B2 (en) 2016-10-05 2022-09-13 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
JP7219705B2 (ja) 2016-10-05 2023-02-08 アクセルロン ファーマ インコーポレイテッド ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20190115037A (ko) * 2017-02-01 2019-10-10 악셀레론 파마 인코포레이티드 면역 활성을 증가시키는데 이용되는 TGFβ 및 ActRII
BR112019023071A2 (pt) * 2017-05-04 2020-06-09 Acceleron Pharma Inc proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
US20210107959A1 (en) * 2018-01-03 2021-04-15 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
CN112292144A (zh) 2018-01-12 2021-01-29 科乐斯疗法公司 激活素受体iib型变体及其使用方法
JP2021512919A (ja) * 2018-02-09 2021-05-20 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
AU2019231791B2 (en) 2018-03-09 2022-08-11 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
JP2021522793A (ja) * 2018-05-03 2021-09-02 アクセルロン ファーマ インコーポレイテッド ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用
KR20210063348A (ko) * 2018-08-28 2021-06-01 이뮤노테크 바이오팜 씨오., 엘티디. 개선된 치료용 t 세포
WO2021011864A1 (en) * 2019-07-18 2021-01-21 Memorial Sloan Kettering Cancer Center METHODS AND COMPOSITIONS FOR TARGETING TGF-β SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
WO2021119136A1 (en) * 2019-12-10 2021-06-17 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension
KR20230002391A (ko) * 2020-03-13 2023-01-05 악셀레론 파마 인코포레이티드 신장 질환 또는 병태를 치료하기 위한 단일-가지 actriia 및 actriib 이종다량체 및 치료 방법
CN112190694B (zh) * 2020-09-17 2023-11-10 南通大学 细胞因子活化素c在治疗神经病理性疼痛方面的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU716893B2 (en) 1995-04-11 2000-03-09 General Hospital Corporation, The Reverse two-hybrid systems
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
DK1670511T3 (da) 2003-09-15 2009-11-23 Res Dev Foundation Cripto-antagonisme af activin- og TGF-B-signalering
WO2005047334A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Igg fc fragment for a drug carrier and method for the preparation thereof
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
CN105001320A (zh) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
CN111518218A (zh) * 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
CN101835485B (zh) * 2007-02-01 2016-10-26 阿塞勒隆制药公司 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
EP2574671B1 (en) 2007-03-19 2016-02-03 National Research Council Of Canada Antagonists of ligands and uses thereof
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
MX2010011998A (es) * 2008-05-02 2011-04-11 Acceleron Pharma Inc Metodos y composiciones de pericitos para regular la angiogenesis y composicion de pericapilar.
WO2009158033A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI748373B (zh) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
CA2737271C (en) 2008-09-17 2020-06-23 National Research Council Of Canada Hetero-multivalent binding agents for members of the tgf.beta. superfamily
LT2370463T (lt) * 2008-11-26 2016-12-12 Amgen Inc. Stabilizuotas aktivino iib receptoriaus variantas
US8338377B2 (en) 2009-03-30 2012-12-25 Acceleron Pharma Inc. BMP-ALK3 antagonists and uses for promoting bone growth
EP3805259A1 (en) 2009-06-12 2021-04-14 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
FR2951408B1 (fr) 2009-10-15 2012-01-13 Renault Sa Cadre moteur pour moteur electrique de vehicule automobile
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
EP3818988A1 (en) * 2009-11-03 2021-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
EP2831105B1 (en) 2012-03-28 2017-08-09 The Board of Regents of The University of Texas System Tgf type ii-type iii receptor fusions
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
WO2016090035A2 (en) 2014-12-02 2016-06-09 La Jolla Institute For Allergy And Immunology Modulators of activin and methods for modulating immune responses and t follicular helper cells
WO2016154601A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
KR20170141215A (ko) 2015-04-06 2017-12-22 악셀레론 파마 인코포레이티드 싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MA54328A (fr) 2015-04-06 2021-10-06 Acceleron Pharma Inc Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
RU2733492C2 (ru) 2015-04-22 2020-10-02 Байоджен Ма Инк. Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
WO2016205370A1 (en) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
WO2018009624A1 (en) 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
JP7219705B2 (ja) 2016-10-05 2023-02-08 アクセルロン ファーマ インコーポレイテッド ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

Also Published As

Publication number Publication date
AU2016246602A1 (en) 2017-10-26
CA2981793A1 (en) 2016-10-13
HUE054180T2 (hu) 2021-08-30
JP2021054839A (ja) 2021-04-08
CY1124247T1 (el) 2022-07-22
MA53883A (fr) 2021-08-18
US10358476B2 (en) 2019-07-23
CN107849114B (zh) 2021-08-20
US11208460B2 (en) 2021-12-28
EP3280727B1 (en) 2021-02-17
CN113683708A (zh) 2021-11-23
JP6810702B2 (ja) 2021-01-06
PT3280727T (pt) 2021-04-23
US20220315642A1 (en) 2022-10-06
EP3280727A1 (en) 2018-02-14
RS61728B1 (sr) 2021-05-31
ES2864850T3 (es) 2021-10-14
AU2021200906B2 (en) 2023-04-06
KR20170141215A (ko) 2017-12-22
US20200055920A1 (en) 2020-02-20
AU2016246602B2 (en) 2020-11-19
WO2016164501A1 (en) 2016-10-13
AU2021200906A1 (en) 2021-03-04
CN107849114A (zh) 2018-03-27
CN113683709A (zh) 2021-11-23
EP3280727A4 (en) 2019-02-13
PL3280727T3 (pl) 2021-07-19
DK3280727T3 (da) 2021-03-15
JP7203807B2 (ja) 2023-01-13
US20160289298A1 (en) 2016-10-06
JP2018517664A (ja) 2018-07-05
HRP20210411T1 (hr) 2021-04-30
LT3280727T (lt) 2021-04-12
HK1252958A1 (zh) 2019-06-06
SI3280727T1 (sl) 2021-07-30
EP3865505A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
MD3280727T2 (ro) Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora
BR112017021510A2 (pt) heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
CY1121025T1 (el) ΑΝΤΙΣΩΜΑ ANTI-cMET
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
EA201792047A1 (ru) Новые соединения
NZ747350A (en) Methods for treating anemia
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
ECSP055699A (es) Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos
BR112014015105A2 (pt) inibidores da via de sinalização notch e uso do mesmo no tratamento de cânceres
EA201100355A8 (ru) Пирролопиримидины и их применение
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
MY182036A (en) Heteroaromatic compounds as pi3 kinase modulators
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
CL2015001483A1 (es) Compuestos derivados de hidroxiquinolina y otros heterociclos nitrogenados, antagonistas de los receptores muscarínicos y agonistas del receptor beta2 adrenérgico; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento o prevencion del asma, bronquitis cronica o epoc.
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
EA201792304A1 (ru) Комбинированная терапия для лечения рака
PE20110572A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO INHIBIDORES DE MET
NO20064771L (no) 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
BR112015006726A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CL2014000007A1 (es) Compuestos derivados de oxazol y tiazol, inhibidores selectivos de proteinas quinasas; composicion farmaceutica; combinacion farmaceutica; su uso en el tratamiento de enfermedades tales como mastocitosis, neoplasia hematologica, trastorno mieloproliferativo, enfermedad autoinmune, enfermedad inflamatoria, alergias o enfermedad neurologica.
JP2017530372A5 (ro)